The global overactive bladder treatment market is projected to reach USD 4.2 Billion by 2027 from USD 3.5 Billion in 2022, at a CAGR of 3.6% during the forecast period Major factors driving the market growth are rising prevalence of overactive bladder syndrome across the globe. Furthermore, launch of novel drugs with lesser side-effects coupled with adoption of technologically advanced treatment options for OAB treatment are also expected to support market growth in the coming years.
Overactive bladder treatment market is fragmented and competitive in nature, several market players are adopting strategies to sustain market competition. The company offerings range from, various drugs, devices and botox that have larger geographic reach along with high product flexibility. Prominent players in the global overactive bladder treatment market are Astellas Pharma (Japan), Teva Pharmaceutical Industries (Israel), Pfizer (US), Medtronic (Ireland), AbbVie (US), Viatris (US), Hisamitsu Pharmaceutical (Japan), Johnson & Johnson Services (US), Endo Pharmaceuticals (Ireland), and among others.
ASTELLAS PHARMA (JAPAN)
Astellas Pharma is a Japanese multinational pharmaceutical company formed from the merger of Yamanouchi Pharmaceutical Co. and Fujisawa Pharmaceutical Co. Astellas Pharma is engaged in the research, development, manufacturing, import, and export of pharmaceutical products. It is one of the leading players operating in the overactive bladder treatment market globally. The company provides two major drugs—Betanis/Myrbetriq/BETMIGA and VESIcare. Myrbetriq is one of the most prescribed medications for overactive bladder disorders. The company has its research & development base in Japan and R&D centers in Europe and other countries across the Asia Pacific. The company operates in more than 70 countries across the globe.
PFIZER (US)
Pfizer is a leading global pharmaceutical company. It develops medicines for a wide range of therapeutic areas, such as metabolic & cardiovascular diseases, inflammation & immunology, neuroscience & pain, oncology, rare diseases, and vaccines. The company operates through three distinct business segments: Biopharma, Pfizer CentreOne, and Consumer Healthcare. In July 2019, the Consumer Healthcare business, an OTC medicines business, was combined with GSK’s Consumer Healthcare business to form a new Consumer Healthcare JV.
The product, TOVIAZ, comes under the Internal Medicine segment of the Biopharma business. The company markets its product Detrol via Viatris. Viatris was formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer.
ABBVIE INC. (US)
AbbVie is a diversified research-based biopharmaceutical company with a comprehensive product portfolio that has leadership positions across immunology, hematologic oncology, neuroscience, aesthetics, and eye care. In May 2020, the company acquired Allergan plc, an American global pharmaceutical company focused on eye care, neurosciences, medical dermatology, medical aesthetics, breast enhancement, obesity intervention, and urology. Allergan provides BOTOX therapeutics, including Vraylar and Ubrelvy. The company provides Enablex, extended-release tablets for overactive bladder treatment.
AbbVie operates through a single business segment. The company’s products are sold worldwide directly to wholesalers, distributors, government agencies, healthcare facilities, specialty pharmacies, and independent retailers from AbbVie-owned distribution centers and public warehouses. The company serves in more than 100 countries across the globe.
Related Links
https://www.marketsandmarkets.com/Market-Reports/overactive-bladder-treatment-market-219938791.html
https://www.marketsandmarkets.com/ResearchInsight/overactive-bladder-treatment-market.asp
https://www.marketsandmarkets.com/PressReleases/overactive-bladder-treatment.asp
